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Available evidence indicates that the CD6 lymphocyte surface receptor is involved in 
T-cell developmental and activation processes, by facilitating cell-to-cell adhesive con-
tacts with antigen-presenting cells and likely modulating T-cell receptor (TCR) signaling. 
Here, we show that in  vitro activation of human T  cells under different TCR-ligation 
conditions leads to surface downregulation of CD6 expression. This phenomenon 
was (i) concomitant to increased levels of soluble CD6 (sCD6) in culture supernatants, 
(ii) partially reverted by protease inhibitors, (iii) not associated to CD6 mRNA down- 
regulation, and (iv) reversible by stimulus removal. CD6 down-modulation inversely 
correlated with the upregulation of CD25 in both FoxP3− (Tact) and FoxP3+ (Treg) T-cell 
subsets. Furthermore, ex vivo analysis of peripheral CD4+ and CD8+ T cells with acti-
vated (CD25+) or effector memory (effector memory T cell, CD45RA−CCR7−) phenotype 
present lower CD6 levels than their naïve or central memory (central memory T  cell, 
CD45RA−CCR7+) counterparts. CD6lo/− T  cells resulting from in  vitro T-cell activation 
show higher apoptosis and lower proliferation levels than CD6hi T cells, supporting the 
relevance of CD6 in the induction of proper T-cell proliferative responses and resistance 
to apoptosis. Accordingly, CD6 transfectants also showed higher viability when exposed 
to TCR-independent apoptosis-inducing conditions in comparison with untransfected 
cells. Taken together, these results provide insight into the origin of sCD6 and the pre-
viously reported circulating CD6-negative T-cell subset in humans, as well as into the 
functional consequences of CD6 down-modulation on ongoing T-cell responses, which 
includes sensitization to apoptotic events and attenuation of T-cell proliferative responses.
Keywords: lymphocyte activation, cD6, T cells, apoptosis, surface receptor down-modulation, T-cell homeostasis
Abbreviations: ADAM, a disintegrin and metalloproteinase; AICD, activation-induced cell death; ALCAM, activated leuko-
cyte cell adhesion molecule; APC, antigen-presenting cell; CLL, chronic lymphocytic leukemia; Geo MFI, geometric mean 
of fluorescence intensity; mDC, mature dendritic cell; rshCD6, recombinant soluble human CD6; SRCR, scavenger receptor 
cysteine-rich; SEB, staphylococcal enterotoxin B; SN, supernatant; TACE, TNF-α-converting enzyme; TCM, central memory 
T cell; TEM, effector memory T cell; Treg, regulatory T cell.
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inTrODUcTiOn
Immune modulation is an active area of medical research for 
development of novel therapies that apply to immune-mediated 
disorders. Most promising targets are co-stimulatory (e.g., CD28) 
and—inhibitory (e.g., CTLA-4) immunoreceptors present at 
the immune synapse (IS)—the site of antigen-presenting cell 
(APC)–T-cell interaction that drives T-cell activation. CD6 is 
lymphocyte surface accessory molecule associating to the T-cell 
receptor (TCR) complex at the center of the IS (1), whose modu-
latory role (either positive or negative) in T-cell activation has 
not been definitively established, in part due to the lack of suit-
able genetically modified animal models. This contrasts with 
the identification of CD6 as a significant susceptibility locus for 
multiple sclerosis in genome-wide association studies (2) and the 
promising results of treating some autoimmune disorders with 
non-depleting anti-CD6 mAb (3).
CD6 is a 105–130 kDa glycoprotein expressed by all thymo-
cytes and mature T cells, a subset of NK and B cells (4, 5), and 
some hematopoietic cell precursors (6), and brain areas (7). 
It is composed of three scavenger receptor cysteine-rich (SRCR) 
extracellular domains, a transmembrane region and a cytoplas-
mic tail without intrinsic catalytic activity but harboring several 
motifs susceptible of phosphorylation and/or interaction with 
signal-transducing effectors (8). Notably, CD6 plays a key role in 
the stabilization and maturation of the IS, as well in subsequent 
T-cell proliferative responses (9–11). This is achieved through 
interaction of membrane-proximal SRCR domain (D3) of CD6 
with the N-terminal domain (D1) of CD166/activated leukocyte 
cell adhesion molecule (ALCAM), a broadly distributed adhe-
sion molecule of the Ig superfamily, expressed by dendritic cells 
(DC), macrophages, B cells, and thymic epithelial cells among 
others (12, 13). The CD6 signaling pathway is only partially 
known and includes the activation of MAPK (14), and recruit-
ment of Syntenin-1 (15) and SH2 domain-containing leukocyte 
protein of 76 kDa (SLP-76) (16). Recently, CD6 has been identi-
fied as a critical protein in the linker for the activation of T cells 
(LAT)-independent TCR signaling scaffold (17).
Changes in CD6 surface levels have been reported under 
both physiologically and experimentally induced conditions, but 
their ultimate significance is not fully understood. In thymus, 
CD6 expression levels seem to be developmentally regulated as 
they increase when immature double-positive thymocytes are 
selected to a mature single-positive stage (18). CD6 upregula-
tion on both immature and mature thymocytes but not PBL is 
efficiently achieved via CD2 compared to CD3 cross-linking 
and correlates well with resistance to apoptosis, suggesting that 
CD6-dependent signals contribute to the positive selection and 
survival of thymocytes (18). Protein kinase C (PKC) activators 
also positively upregulate CD6 expression on both peripheral 
T  cells and thymocytes but only negligibly on lymphoblastoid 
B-cell lines (19). Studies in herpes virus-infected patients showed 
a reduced expression of CD6, CD28, and CD5 on CD8+ T cells that 
expand after viral infection, while the CD4+ T cells maintained 
normal levels of these markers (20). Interestingly, such a CD8+ 
T-cell population was more susceptible to both spontaneous and 
activation-induced cell death (AICD) (20). An intriguing finding 
was also the discovery of a small subset of peripheral blood 
T  cells from healthy subjects (5–6% of CD3+ cells) expressing 
little or no CD6 (CD3+CD5intCD6lo/−) in both the CD4+ and CD8+ 
subsets (21). These CD6lo/− T cells were reported as of unknown 
precursor origin and showed substantially reduced reactivity 
to allogeneic stimulation but not to mitogenic lectins (PHA) 
or soluble recall antigens (tetanus toxoid) (21). Recently, it has 
been reported that human natural regulatory T cells (nTreg) are 
characterized by low/negative expression of CD6 (22), and the 
authors hypothesized that it could be the same CD6lo/− population 
identified by Rasmussen et al. (21).
The existence of a soluble CD6 (sCD6) form of unknown 
origin and circulating at very low levels (pico/nano molar range) 
in sera from healthy individuals has also been reported (23). 
Interestingly, elevated sCD6 levels were observed in patients suf-
fering of primary Sjögren’s syndrome (24) and systemic inflam-
matory response syndrome (25), although a direct mechanistic 
and/or functional relationship between the two events is lacking.
The present study analyzes CD6 expression following differ-
ent in vitro T-cell stimulatory conditions. The results reported 
herein indicate that CD6 is down-modulated in part due to 
proteolytic cleavage, and this contributes to homeostatic control 
of ongoing immune responses by making T cells more prone to 
apoptosis and less responsive to proliferative stimuli.
MaTerials anD MeThODs
cells
PBL were obtained by standard Ficoll gradient (d = 1,077) and 
further depletion of plastic-adherent cells from peripheral blood 
of healthy volunteers from the Banc de Sang i Teixits of Catalonia. 
Written informed consent was obtained from all donors. The 
study was carried out according to the recommendation and 
approval of the Ethics Committee of Clinical Investigation from 
the Hospital Clinic of Barcelona. The human Jurkat T-lymphoma 
cell line was from the American Tissue Culture Collection. The 
parental and CD6-transfected 2G5 Jurkat derivative cells (CD5− 
and CD6−) were generated as reported elsewhere (14, 26). Unless 
otherwise indicated, cells were cultured in RPMI 1640 (Lonza) 
medium supplemented with 10% FBS (Gibco) and gentamicin 
(0.5 µg/mL, Braun).
antibodies and reagents
The anti-CD6 161.8 (IgG1) and OX124 (IgG1) mAbs were kindly 
provided by Ramón Vilella (Immunology Department, Hospital 
Clínic, Barcelona) and Steven Cobbold (University of Oxford, 
Oxford, UK), respectively. Recombinant soluble human CD6 
(rshCD6) and CD5 (rshCD5) were produced as previously 
reported (9, 23). Staphylococcal enterotoxin B (SEB) was from 
Sigma.
Flow cytometry analyses and cell sorting
Human PBL were suspended in PBS containing 2% FBS for 
30 min on ice and, then, stained with different combinations of 
fluorochrome-labeled mAb: CD6-FITC (M-T605), CD4-FITC 
(L200), CD45RA-PerCP-Cy™5.5 (HI100), and CD25-APC-H7 
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(M-A251) from BD Pharmingen; CD3-APC-Cy™7 (SP34-2), 
CD3-PE (UCHT1), CD25-V450 (M-A251), IgG1k-PE (MOPC-
21), IgG1k-APC (MOPC-21), and CD197/CCR7-PE (3D12) 
from BD Biosciences; CD3-APC (MEM-57) and CD25-APC 
(MEM-181) from Immunotools; CD8-APC (HIT8a), CD8-Pacific 
Blue™ (SK1), CD27-Pacific Blue™ (M-T271), CD178/FasL-PE 
(NOK-1), and CD95/Fas-PerCP-Cy5.5 (DX2) from Biolegend; 
CD4-Alexa Fluor®647 (MT310) from Santa Cruz Biotechnology; 
CD5-PerCP-Cy5.5 (UCHT2) from TONBO Biosciences; and 
goat anti-mouse Ig-FITC from Sigma. Treg cells were detected 
by intracellular FoxP3 staining kit (BD Pharmingen) following 
manufacturer’s instructions. Cell viability and apoptosis assays 
were performed by using Live/Dead Fixable Violet Dead stain 
kit (Life Technologies), Annexin V-FITC (Apoptosis Detection 
kit; Life technologies) or Annexin V-PE (BioLegend) and 7-AAD 
(BD Pharmingen), following manufacturer’s instructions. Cells 
were run on a FACS Canto II instrument (BD Bioscience) and 
analyzed by FlowJo software.
For cell sorting purposes, PBL (5 × 106 cells) was harvested at 
day 3 post-PHA activation (2 µg/mL; Sigma), suspended in PBS 
plus 2% FBS and 2 mM EDTA, and then labeled for CD3, CD6, 
and CD25 expressions. Nonviable cells were discarded using 
Live/Dead Fixable Violet Dead stain kit. The desired T-cell sub-
sets (CD3+CD25+CD6hi) and (CD3+CD25+CD6lo/−) were sorted 
on a FACSAria III machine (BD Bioscience), further stained 
with Cell trace™ CFSE Cell Proliferation kit (Life Technologies), 
and cultured for an additional 6 days. At days 2 and 6, cells were 
analyzed for apoptosis and proliferation.
T-cell stimulation assays
PBL (105 cells/well) were cultured with PHA (5 µg/mL), anti-CD3 
plus anti-CD28 (αCD3/CD28) dynabeads (2  μL/105 cells; Life 
Technologies), PMA (10  ng/mL; Sigma), or rhIL-2 (10  ng/mL; 
Roche) in X-VIVO™15 medium (Lonza) for 4  days at 37°C. 
In some experiments, at day 3 of culture, cells were stimulus-
deprived and then re-stimulated with PHA (1  µg/mL) or left 
untouched for an additional 13-day period. Protease inhibitor 
TAPI-2 (100  mM; Sigma) or Complete™ (Roche) effects were 
tested on PHA-activated (2 µg/mL) PBL.
For T-cell proliferation assays, PBLs (105  cells/well) were 
labeled with CFSE and co-cultured with 2 × 103 SEB preloaded 
mature DCs (mDCs) from an unrelated donor and generated as 
described elsewhere (27). In some experiments, at day 5, cells 
were analyzed for CD6 surface expression with biotinylated 
161.8 mAb (2 µg/mL) plus Streptavidin (SAv)-Alexa Fluor® 700 
(Invitrogen). Percent of proliferating cells and number of cell 
cycles were determined by measuring the geometric mean of 
fluorescence intensity (Geo MFI) channel of CFSElo and CFSEhi 
cells by flow cytometry and the FlowJo software.
Detection of scD6
ELISA detection of human sCD6 was performed on 96-well 
microtiter plates (Nunc, Roskilde, Denmark) coated overnight 
(o/n) at 4°C with PBL supernatants (SN) (100 µL). After block-
ing for 1  h at room temperature (RT) with PBS plus 3% BSA, 
biotinylated 161.8 mAb (2 µg/mL) was added and incubated for 
2 h at RT. Bound mAb was detected by 1 h incubation at RT with 
SAv-Peroxidase (SAv-POD; Roche) and further color develop-
ment by the addition of 3,3′,5,5′-tetramethylbenzidine liquid 
substrate (Sigma). Absorbance was measured at 450  nm with 
Epoch spectrophotometer (BioTek).
For immunoprecipitation of sCD6, protein G sepharose beads 
(GE Healthcare Life Sciences) were coupled to 161.8 mAb fol-
lowing manufacturer’s instructions and, then, incubated o/n at 
4°C under orbital rotation with 1 mL SN from PHA- or rhIL-2-
treated PBL. RshCD5 (500 ng) and rshCD6 (500 ng) were used as 
negative and positive controls, respectively. After washings, beads 
were eluted and run on 8% SDS-PAGE under reducing conditions 
for further Western blot analysis with rabbit anti-human CD6 
antiserum (1:500) produced in our laboratory (27), followed 
by HRP-labeled donkey anti-rabbit Igs (GE Healthcare Life 
Sciences). Chemiluminescence was developed with Supersignal 
West Dura Extended Duration Solution (Pierce, Rockford, 
IL, USA) and images were obtained using ImageQuant LAS 4000 
(GE Healthcare Life Sciences).
Western Blot analysis
Cells were lysed after a 30  min incubation on ice with lysis 
buffer (10 mM Tris-HCl pH 7.6, 140 mM NaCl, 5 mM EDTA, 
140 mM NaF, 0.4 orthovanadate, 5 mM pyrophosphate, 1 mM 
phenylmethylsulfonyl fluoride, protease inhibitor mixture tablets 
(Complete™), and 1% non-idet P-40). After centrifugation at 
12,000 ×  g for 15  min at 4°C, Laemmli’s buffer was added to 
50  µL from cell lysates. Samples were boiled and run on 8% 
SDS-PAGE under reduction conditions for further WB analysis. 
Membranes were incubated with rabbit anti-human CD6 poAb 
(1:500), followed by anti-rabbit-HRP (1:2,500) (Roche). Chem-
iluminescence was developed with Supersignal West Dura 
Extended Duration Solution (Pierce, Rockford, IL, USA). Images 
were obtained using LAS 4000, and bands were quantified with 
Photoshop CS5 software.
Quantitative reverse Transcription Pcr 
(rT-qPcr) assays
Total RNA from non-treated or 24 h treated with rhIL-2 (10 ng/mL), 
PHA (5 µg/mL), or PMA (10 ng/mL) PBMC cells was obtained 
with PureLink RNA Mini Kit (Ambion, Life technologies) accord-
ing to manufacturer’s instructions. RNA was retrotranscribed 
into cDNA using the High capacity cDNA Reverse Transcription 
kit (Thermofisher). RT-qPCR was performed on an Applied 
Biosystems 7900 HT Fast Real Time PCR System using Taqman 
Fast universal PCR master Mix (Life Technologies/ThermoFisher) 
and CD6 specific TaqMan expression assays (Hs00198752_m1: 
exon boundary 1–2) and (Hs00945709_m1: exon boundary 5–6) 
(ThermoFisher Scientific). Results in triplicates were normal-
ized to gycleraldehyde-3-phosphate dehydrogenase (GAPDH, 
Hs99999905_m1), using the 2ΔCt formula, where ΔCt  =  Ct 
(GADPH) −  Ct (gene of interest). Results are represented as 
relative values.
cytotoxicity assays
Parental and CD6-transfected 2G5 cells were treated with dif-
ferent concentrations of doxorubicin (0.1–10 µM, Pfizer), PHA 
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(2 µg/mL), or puromycin (0.25–2.5 µg/mL) for 24–48 h at 37°C 
in culture medium and, then, analyzed by flow cytometry for 
apoptosis cell detection with Annexin V-FITC or Annexin V-PE 
and 7-AAD.
statistical analyses
Data are expressed as the mean ± SD or SEM using GraphPad 
software. Significant differences between two groups were deter-
mined by using unpaired Student’s t-test and between three or 
more groups with one-way ANOVA followed by Tukey’s test.
resUlTs
cD6 surface expression is Downregulated 
following T-cell activation
CD6 is highly expressed on major human T-cell subsets 
(CD3+CD4+ and CD3+CD8+) from resting PBLs (Figures 1A–C). 
However, following TCR-mediated activation with either PHA 
(5  µg/mL) or anti-CD3 plus anti-CD28 beads (αCD3/CD28) a 
significant and sustained reduction of CD6 surface levels was 
observed in both peripheral T-cell subsets compared to unstimu-
lated cells cultured in the presence of rhIL-2 (Figures  1A–C). 
As expected from previous reports (18), CD6 expression was 
upregulated by PMA (10  ng/mL), a potent polyclonal T-cell 
activator overcoming the need for TCR-ligation (Figures 1A,B). 
Since the T-cell activating agents used above (PHA, PMA, and 
αCD3/CD28) might result in supra-physiological responses, 
changes in CD6 surface expression were analyzed following a 
more physiological cell contact-dependent TCR stimulation 
system. To this end, CFSE-labeled PBL was co-cultured for 5 days 
with SEB pre-loaded allogeneic mDCs and proliferating (CFSElo) 
and non-proliferating (CFSEhi) cells were analyzed for CD6 
expression. As illustrated by Figure 1D, CFSElo cells showed a sig-
nificant reduction of CD6 expression, as measured by Geo MFI, 
compared to CFSEhi cells. These results support the notion that 
CD6 downregulation is an integral late event of TCR-mediated 
T-cell activation. Furthermore, CD6 downregulation was specific 
since the expression of CD5, a closely related lymphoid receptor 
partly associating with CD6 (28), was upregulated under the same 
stimulatory conditions (Figure S1 in Supplementary Material), 
according to previously reported data (29).
cD6 expression inversely correlates  
with cD25 expression following T-cell 
activation regardless of FoxP3 induction
To further confirm that downregulated CD6 expression was 
linked to T-cell activation, PBLs were double stained for CD25 
and CD6 expression at different time points following stimulation 
with αCD3/CD28 beads, PHA (2 μg/mL) or rhIL-2 (10 ng/mL). 
As shown in Figures  2A–C, both CD4+ and CD8+ T  cells 
increased their CD25 expression post-stimulation with αCD3/
CD28 or PHA and concomitantly decreased that of CD6 at later 
time points (96 h in the represented case). It is noteworthy that 
CD6 down-modulation could be detected at even earlier time 
points depending on the donor and the use of high PHA doses 
(5 µg/mL) (Figure S2 in Supplementary Material).
Next, CD6 downregulation was explored in different activated 
CD4+ PBL subsets (CD25hiFoxP3− and CD25hiFoxP3+) result-
ing from PHA stimulation. As illustrated by Figure 2D, lower 
CD6 surface levels were observed for CD25hi cells, irrespec tive 
of their FoxP3 phenotype, compared to unstimulated naïve CD25− 
cells. This indicates that CD6lo/− expression is characteristic of 
CD25hi T cells but do not strictly correlate with FoxP3 expression.
cD6 expression is Downregulated on 
effector but not central Memory T-cells
Demonstration of CD6 down-modulation occurrence ex vivo  
was obtained by analyzing CD6 expression on the small pop-
ulation of peripheral CD25+ T  cells from healthy donors. 
The results showed significantly lower CD6 surface levels on 
both CD4+CD25+ and CD8+CD25+ cells compared to their 
CD25− counterparts (Figure 3A), according to our in vitro data. 
Similar studies were then extended to other peripheral T-cell 
populations related to signal strength and/or extent during T-cell 
activation events, namely central [central memory T cell (TCM)] 
and effector [effector memory T cell (TEM), TEMRA] memory cells 
(30, 31). As shown in Figures 3B,C, significant lower CD6 surface 
expression levels were observed in TEM and TEMRA cells from both 
CD4+ and CD8+ compartments compared to naïve and TCM cells. 
Within TEM and TEMRA populations, the lowest CD6 surface levels 
were observed among the late subset, which expresses low/nega-
tive levels of CD27 (CD27lo/−) (Figures 3B,C), a co-stimulatory 
molecule of the TNFR family involved in the maintenance of 
proliferative capabilities of activated T cells and the generation 
of T-cell memory (32). Taken together, these results support that 
CD6 downregulation also occurs in vivo in the context of activa-
tion-related phenomena and effector memory T-cell generation.
cD6 Down-Modulation is Dependent  
on intracellular ca2+ influx
To get some mechanistic insight into CD6 down-modulation, the 
effect of different pharmacological agents was explored. As shown 
in Figure  4A, ionomycin (0.7  µg/mL) either alone or in com-
bination with PMA (10 ng/mL) down-modulated surface CD6 
expression to a similar extent than induced by PHA (5 µg/mL), 
indicating that Ca2+ influx-dependent events are involved in 
CD6 down-modulation. These data, together with the fact that 
PMA stimulation increased CD6 expression, implies that PKC 
does not play a relevant role in CD6 downregulation. Finally, the 
selective inhibitor of MAP kinase kinases (MEK1/2) U0126 was 
unable to reverse the effects of PHA stimulation (Figure  4A), 
arguing also against a relevant contribution of the MAPK path-
way in the down-modulation of surface CD6 expression.
cD6 Down-Modulation Does not involve 
changes in cD6 isoform Utilization or 
mrna levels
T-cell activation has been reported to upregulate the expression 
of an alternatively spliced CD6 extracellular isoform (CD6ΔD3) 
lacking the CD166/ALCAM-binding domain (D3) (33). To explore 
this possibility as a temptative cause for CD6 down-modulation, 
FigUre 1 | Downregulation of CD6 surface expression in response to different T-cell receptor-mediated activation stimuli. (a–c) PBLs (105/well) were cultured for 
4 days in the presence of PHA (5 μg/mL), αCD3/CD28 beads (2 μL/105 cells), PMA (10 ng/mL), or rhIL-2 (10 ng/mL). Cells were then stained with labeled specific 
mAbs for CD3 (UCHT1), CD4 (MT310), CD8 (SK1), and CD6 (M-T605) and analyzed by flow cytometry at different days (d). (a) Representative dot plots of CD6+ 
cells in the CD3+CD4+ (top panel) or CD3+CD8+ (bottom panel) subsets at days 0 and 4 post-stimulation. (B) Bar chart representing mean ± SD of geometric mean 
of fluorescence intensity (Geo MFI) values for CD6 expression on CD3+CD4+ (top panel) and CD3+CD8+ (bottom panel) cells over time post-stimulation, from three 
independent experiments. (c) Line chart representing the percentage of CD6+ cells over time post-stimulation in the CD3+CD4+ (left hand) or CD3+CD8+ (right hand) 
subsets from three independent experiments. (D) Staphylococcal enterotoxin B-pulsed mature DCs (2 × 103/well) co-cultured with CFSE-labeled PBL (105/well) for 
5 days were analyzed for CD6 expression on proliferating (CFSElo) and non-proliferating (CFSEhi) cells. Left, representative histogram of CD6 expression on CFSElo 
and CFSEhi cells is. Right, bar chart representing percent (mean ± SEM) of CD6+ cells in the CFSElo and CFSEhi subsets from 10 independent experiments. 
***p < 0.001 (unpaired t test).
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FigUre 2 | Continued
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FigUre 2 | Downregulation of CD6 surface expression on CD25+ cells following T-cell activation. (a–c) PBLs (105/well) cultured in the presence of αCD3/CD28 
(2 μL/105 cells) PHA (2 µg/mL) or rhIL-2 (10 ng/mL) for 4 days, were stained with labeled CD3 (UCHT1), CD4 (MT310), CD8 (SK1), CD5 (UCHT2), CD6 (M-T605), 
and CD25 (M-A251) mAbs for flow cytometry analysis at different time points. (a) Left, representative dot plot of CD6 and CD25 expression over time on CD4+ (top 
panel) and CD8+ (bottom panel) cells upon αCD3/CD28 stimulation. Right, line chart representing the percent of CD6+ or CD25+ cells in CD4+ (top panel) or CD8+ 
(bottom panel) cells over time. (B) The same as in (a) but upon culture of cells with PHA (2 µg/mL). (c) The same as in (a) but upon culture of cells with rhIL-2. Data 
represented in (a–c) are the mean ± SD from three independent experiments. (D) PBL (105/well) stained for surface CD4, CD25, and CD6 (see above) and 
intracellular FoxP3 before and after exposure to PHA (2 µg/mL) for 4 days were analyzed by flow cytometry. Top left, representative dot plot of the gating strategy 
used. Top right, bar chart showing the percent of CD4+ cells with CD25−, CD25hiFoxP3−, and CD25hiFoxP3+ phenotype. Bottom left, representative histogram of 
CD6 surface levels on CD25−, CD25hiFoxP3−, and CD25hiFoxP3+ T-cell subsets. Bottom right, bar chart showing the mean ± SD of geometric mean of fluorescence 
intensity values for CD6 expression of triplicates from two experiments. *p < 0.05 (unpaired t test).
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PBLs were stained with different anti-CD6 mAbs at different 
time points post-PHA stimulation. As illustrated in Figure  4B 
(Figure S2 in Supplementary Material), the downregulated CD6 
expression was detectable by the 161.8 mAb (14) but also the 
non-overlapping M-T605 (recognizing the amino-terminal D1 
domain) (11) and OX124 (recognizing the CD166/ALCAM-
binding D3 domain) mAbs (10) in a time- and dose-depending 
manner. This would indicate that CD6 down-modulation involves 
reduced surface expression of full-length and/or D3-deficient 
(CD6ΔD3) isoforms.
Next, putative changes in CD6 mRNA expression levels 
following T-cell activation were further assessed by RT-qPCR 
using probes specific for the exon 1–2 boundary (present in all 
reported CD6 isoforms) or the exon 5–6 boundary (absent from 
CD6ΔD3 isoforms). As illustrated in Figure 4C, PMA increased 
the levels of CD6 mRNA while both PHA and rhIL-2 did not 
induce significant changes. This would argue against reduced 
CD6 transcription as a cause of surface CD6 down-modulation 
following T-cell activation.
scD6 is released following T-cell 
activation
Next, it was explored whether the decreased surface CD6 
expression could result from proteolytic cleavage of the 
membrane-bound form as previously reported for CD5 (34). 
The ELISA analysis of culture SN from PBLs stimulated with 
αCD3/CD28 (Figure  5A) or PHA (Figures  5C,D) showed 
significant increased levels of sCD6 from day 2 compared with 
cells exposed to rhIL-2. Western blot analysis of CD6 immu-
noprecipitates from αCD3/CD28-activated cell SN rendered a 
CD6-reactive band with similar molecular mass (~70  kDa) to 
rshCD6 used as a positive control (Figure 5B). Reactivity was not 
observed in immunoprecipitates from rhIL-2 treated SN or from 
recombinant rhsCD5 (Figure  5B). The addition of a protease 
inhibitor cocktail (Complete™) significantly reduced, though 
incompletely, both the release of sCD6 and the surface CD6 
down-modulation (Figure  5C) from activated PBLs. Similar 
results were obtained using TAPI-2 (Figure 5C), a broad metal-
loproteinase inhibitor (35) with relative specificity for TNF-α-
converting enzyme (TACE; also named ADAM17), an enzyme 
involved in the shedding of several surface proteins including the 
CD6 ligand (CD166/ALCAM) (36). No differences in cell viabil-
ity were detected at the end of the stimulation period among all 
the samples analyzed (data not shown). Altogether, these results 
suggest that activation-induced surface CD6 down-modulation 
may result, at least in part, from proteolytic release involving 
members of the ADAM (a disintegrin and metalloproteinase) 
family.
FigUre 3 | Ex vivo analysis of CD6 surface expression on peripheral T cells with activated or memory phenotypes. (a) Bar chart representing geometric mean of 
fluorescence intensity (Geo MFI) (mean ± SEM) of CD6 surface expression on CD25− and CD25+ peripheral CD4+ (left hand side) and CD8+ (right hand side) T cells 
from healthy donors (n = 4). (B) Analysis of CD6 surface expression of peripheral CD4+ T cells from healthy donors with naïve (CD45RA+CCR7+), central memory 
T cell (CD45RA−CCR7+), effector memory T cell (TEM) (CD45RA−CCR7−), and TEMRA (CD45RA+CCR7−) phenotypes. A representative dot plot of the gating strategy 
used is shown (top left). The bar chart shows the relative CD6 surface expression on the indicated subsets from five different donors (top right). Data represent the 
percent (mean ± SEM) increase/reduction of Geo MFI values for each subset considering 100% the values for naïve T cells. *p < 0.05; **p < 0.01; ***p < 0.001 
(unpaired t test). Lower panel, CD6 surface levels on late (CD27lo/−) and early (CD27hi) CD4+ TEM (left), and TEMRA (right) cells. AU, autofluorescence. (c) Same as in  
(B) but for CD8+ peripheral T cells.
8
Carrasco et al. CD6 Down-Modulation Impacts T-cell Homeostasis
Frontiers in Immunology | www.frontiersin.org June 2017 | Volume 8 | Article 769
FigUre 4 | CD6 down-modulation is dependent on Ca2+ influx and does not involve differential utilization of extracellular CD6 isoforms nor changes in CD6 mRNA 
levels. (a) PBL (2 × 105/well) was cultured for 2 (left) or 4 (right) days in the presence of rhIL-2 (10 ng/mL) alone, or together with PMA (10 ng/mL), PMA (10 ng/mL) 
plus Ionomycin (0.7 µg/mL), Ionomycin (0.7 µg/mL), PHA (5 µg/mL), and PHA plus U0126 (10 µM). Cells were stained with labeled mAb for CD3 (UCTH1) and CD6 
(M-T605) and analyzed by flow cytometry. Shown is a bar chart representing the mean ± SD of geometric mean of fluorescence intensity (Geo MFI) values for CD6 
expression. (B) PBLs (105/well) cultured for 3 days in the presence of 2 µg/mL (top panel) or 5 µg/mL (bottom panel) of PHA were analyzed by flow cytometry for 
CD6 surface expression with either FITC-labeled M-T605 mAb or unlabeled OX124 and 161.8 mAb plus FITC-labeled goat anti-mouse Ig. Bars represent the 
percent (mean ± SEM) of CD6+ PBL at different time points following exposure to PHA, from three independent experiments performed. Comparisons were made 
with values at day 0. *p < 0.05; **p < 0.01; ***p < 0.001 (unpaired t test). (c) Reverse transcription PCR analysis of CD6 mRNA levels following 24 h stimulation of 
PBMC with PHA (5 µg/mL), PMA (10 ng/mL), or rhIL-2 (10 ng/mL). Left, results obtained with an exon 1–2 boundary-specific probe. Right, results obtained with an 
exon 5–6 boundary specific. Data are presented as mean ± SD (n = 4). *p < 0.05 (Student’s t-test).
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FigUre 5 | Continued
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cD6 surface expression recovers after 
stimulation Deprival
The putative reversibility of PHA-induced CD6 downregulation 
on CD4+ T cell was next investigated by analyzing CD6 and CD25 
expressions upon re-stimulation with PHA, PHA deprivation (by 
extensive washing), or left untouched for an additional period of 
time (Figure 5D). PHA-deprived cells gradually recovered CD6 
expression over time, while it stayed low for PHA re-stimulated 
cells. In a similar manner, CD25 expression level gradually 
decreased once the cells were PHA deprived or left untouched, 
while it remained high upon PHA re-stimulation. Accordingly, 
sCD6 levels in culture SNs slowly declined unless cells were re-
stimulated (Figure 5D, right hand side). This indicates that CD6 
FigUre 5 | Continued  
Activation-induced CD6 down-modulation involves shedding by proteolytic ectoenzymes, and CD6 surface expression recovers after the removal of activating 
stimuli. (a) Supernatants (SN) (100 µL) from PBLs (105/well) cultured in the presence of αCD3/CD28 (2 µL) or rhIL-2 (10 ng/mL) were sampled daily for soluble CD6 
(sCD6) release by ELISA. Data are expressed as percent (mean ± SEM) of A450 nm values from three experiments performed taking as 100% the values obtained from 
4-day αCD3/CD28-stimulated samples. (B) SN from PBLs (1–2 × 106/well) cultured for 4 days as in (a) was immunoprecipitated with 161.8 mAb coupled to protein 
G sepharose beads. Recombinant soluble human CD6 (rshCD6) and rshCD5 (500 ng each) were included as positive and negative immunoprecipitation controls. 
Shown are chemiluminiscent results of Western blotting immunoprecipitates with rabbit anti-CD6 antiserum plus HRP-labeled donkey anti-rabbit Igs. Purified 
rshCD6 (500 ng) was included as a positive control for Western blot. (c) PHA-stimulated (2 µg/mL) PBL were cultured for 4 days in the presence or absence of 
TAPI-2 (100 mM), Complete™, or rhIL-2 (10 ng/mL). Left, bar chart showing the ELISA analysis of sCD6 in culture supernatants as done in (a). Right, bar chart 
showing the geometric mean of fluorescence intensity (Geo MFI) (mean ± SEM) values for CD6 surface expression from three experiments performed. Comparisons 
were made with cells cultured with rhIL-2. **p < 0.01; ***p < 0.001 (unpaired t test). (D) PHA-stimulated (1 µg/mL) PBLs (105/well) for 3 days (arrow) were either 
stimulus deprived by extensive washing (open circles), re-stimulated with PHA (open triangles), or left untouched (closed circles) for additional days of culture. 
Results represent the percent (mean ± SEM) of CD6+ (left) and CD25+ (middle) cells in the CD4+ subset from three different experiments. The right hand line chart 
shows sCD6 levels measured as in (a) and expressed as percent increase/decrease of A450 nm values considering 100% the values obtained from 3-day PHA-
stimulated samples. (e,F) Whole cell extracts from αCD3/CD28-stimulted PBMC for 0–6 days were western blotted for anti-CD6 reactivity. Shown is the 
chemiluminiscent results (e) together with densitometry analysis of i (F) and ii (g) bands with ImageJ software (AU, arbitrary units). The experiment shown is 
representative of four performed from different PBMC donors.
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downregulation reverses in  vitro if cells are no longer actively 
stimulated.
Western blot analysis of whole cell extracts from PBLs stimu-
lated or not with αCD3/CD28 revealed two CD6-reactive bands 
of ~115 and ~75 kDa (Figures 5E–G), likely corresponding to 
fully processed membrane-bound and unprocessed intracellular 
forms, respectively (37). While the intensity of the ~75 kDa band 
remained mostly unchanged over time, there was a drop in the 
intensity of the ~115 kDa band at day 2 post-αCD3/CD28 stimu-
lation that recovered by day 6 (Figures 5E–G). This result mimics 
the above reported kinetic analysis of surface CD6 expression 
(Figure  5D) and supports the assumption that the ~115  kDa 
band corresponds to membrane-bound CD6.
cD6 Downregulation correlates with 
increased susceptibility to apoptosis
The functional significance of CD6 down-modulation upon 
T-cell activation was further explored by analyzing the number 
of live/apoptotic cells, as well as the expression of surface markers 
from the TNF superfamily (CD27, CD95/Fas, and CD178/FasL) 
on CD6+ versus CD6lo/− activated T cells (CD3+CD25+). As illus-
trated by Figure 6A, 3-day αCD3/CD28 stimulation resulted in 
the appearance of CD25+CD6lo/− cells showing significant lower 
levels of live cells compared to CD25+CD6+ or unstimulated 
CD25−CD6+ cells (day 0), as determined by forward and side 
scatter analyses. Moreover, compared with CD25+CD6+ cells, 
CD25+CD6lo/− cells expressed significant lower surface levels 
of CD27, a co-stimulatory molecule (38) involved in resistance 
to apoptosis (Figure  6B). In contrast, the CD25+CD6lo/− cells 
expressed significant higher surface levels of the AICD markers 
CD95/Fas and CD178/FasL than CD25+CD6+ cells (Figure 6C). 
These results suggest that reduction of CD6 surface levels corre-
lates with a reduced T-cell viability and with markers of increased 
sensibility to apoptosis.
As PMA-induced activation upregulates CD6 expression, 
we also compared the apoptosis levels among PMA-activated 
T  cells expressing different CD6 surface levels. The analysis of 
cell viability by annexin V and 7-AAD criteria indeed showed a 
higher frequency of viable cells among PMA-stimulated PBMC 
with higher CD6 surface levels compared with those expressing 
lower ones (Figure 6D). Thus, higher CD6 upregulation also cor-
relates with higher viability among PMA-stimulated cells.
sorted cD25+cD6hi and cD25+cD6lo/−  
T cells Differ in Their Proliferative 
responses
In another set of experiments, the functional capabilities of sorted 
PHA-activated CD25+CD6lo/− and CD25+CD6hi T cells (Figure S3 
in Supplementary Material) were further explored by culturing 
them for an additional 6-day period and assessing their viability 
and proliferative responses. As illustrated in Figure  7A, the 
number of viable CD25+CD6lo/− cells decreased over time when 
they were left unstimulated, while that of CD25+CD6hi signifi-
cantly increased during the same period of time, as measured by 
trypan blue dye exclusion. Moreover, FACS analysis of the same 
cells co-stained with Annexin-V-FITC and 7-AAD (Figure 7B) 
showed both a significant reduction of live cells and an increase 
in early apoptotic cells within the CD25+CD6lo/− subset compared 
to CD25+CD6hi cells.
The proliferative responses of sorted PHA-activated 
CD25+CD6hi and CD25+CD6lo/− T cells were also investigated by 
co-culture with SEB-loaded allogeneic mDCs. As illustrated in 
Figures 7C–E, CD25+CD6lo/− T cells showed a significant lower 
percentage of CFSElo/− cells as compared to their CD25+CD6hi 
counterparts. Taken together, these results further support that 
CD6 downregulation correlates with apoptosis and reduced 
proliferative capabilities of T cells.
Modulation of cD6 expression influences 
the survival of leukemic T cells
The protective effect of CD6 expression on TCR-induced apopto-
sis would agree with previous reports showing that CD6 ligation 
prevents IgM cross-linking-induced apoptosis of leukemic B cells 
(chronic lymphocytic leukemia) (39). It was then investigated 
whether surface CD6 expression influences apoptosis induced 
by genotoxic agents overcoming the need of signaling via TCR. 
To that end, we used untransfected and CD6-transfected 2G5 
cells, a CD6-deficient Jurkat T-cell derivative (14, 26) (Figure 8A). 
As shown in Figure  8B, 2G5 cell transfectants underwent 
FigUre 6 | Continued
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FigUre 6 | Continued  
CD6 surface expression inversely correlates with T-cell viability. PBL (105/well) exposed to αCD3/CD28 for 3 days was analyzed at days 0 and 3 by flow cytometry 
for cell viability and the expression of survival/apoptosis-related surface markers (CD3, CD25, CD6, CD27, CD95, and CD178). (a) Representative dot plots of live 
and apoptotic cells from day 0 (unstimulated) CD25−CD6+ cells (top panels) and day 3 αCD3/CD28-activated CD25+CD6+ and CD25+CD6lo/− cells (bottom panels) 
as determined by FSC and SSC criteria. At the top right hand side, a bar chart is shown representing the percent of live cells in the indicated unstimulated (day 0, 
CD25−CD6+) and activated (day 3, CD25+CD6+ and CD25+CD6lo/−) T cells. (B) Representative dot plot analysis of CD27 expression versus SSC in the same days 0 
and 3 cells as in (a). The bar chart represents the percent of CD27+ cells in CD25−CD6+ cells (day 0) and CD25+CD6+ and CD25+CD6lo/− cells (day 3). (c) Bar chart 
represents geometric mean of fluorescence intensity (mean ± SD of triplicates) of FasL (left) and Fas (right) expressions from same subsets as in (a) and are 
representative of two experiments. *p < 0.05; **p < 0.01; *** p < 0.001 (unpaired ANOVA test followed by Tukey’s multiple comparison test). (D) PBL (2 × 105/well) 
were cultured for 24 h in the presence of rhIL-2 (10 ng/mL) plus PMA (10 ng/mL) and stained with labeled mAb for CD3 (MEM-57-APC), CD6 (M-T605-FITC), 
7-AAD, and Annexin-PE. Left, representative dot plots of gated CD3+CD6lo/– and CD3+CD6hi cells post-PMA stimulation stained for Annexin V-PE and 7-AAD. Right, 
bar chart showing the percent (mean ± SEM) of live (Annexin-V– 7-AAD–), early apoptotic (Annexin-V+ 7-AAD–), and late apoptotic (Annexin-V+ 7-AAD+) cells from 
PMA-stimulated CD3+CD6lo/− and CD3+CD6hi cells. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t-test).
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down-modulation of CD6 surface expression by days 1 and 2 
post-PHA activation, in a similar manner to that observed for 
peripheral T cells. Furthermore, CD6-transfected 2G5 cells were 
consistently more resistant to apoptosis induced by doxorubicin 
(0.1–10  µM) or puromycin (0.25–2.5  µg/mL) than parental 
(untransfected) cells (Figure 8C). These data support the notion 
that CD6 rescues lymphocytes from apoptosis induced also by 
TCR-independent pathways.
DiscUssiOn
The current view is that CD6—through its interaction with 
CD166/ALCAM—is involved in positive selection and survival 
of developing mouse thymocytes (18, 40), as well as in early 
adhesive APC–T-cell contacts driving to formation of mature 
IS and further proliferative responses of human T cells (9–11). 
In the present work, evidence is provided on the involvement of 
CD6 down-modulation in the regulation of late human T-cell 
activation events, rendering cells hyper-sensitive to apoptosis 
and hypo-responsive to further proliferative stimulation.
Surface downregulation of CD6 was observed on resting human 
T  cells upon in  vitro activation with different TCR-dependent 
stimuli (PHA, αCD3/CD28, and SEB-loaded allogeneic mDC), 
which in turn upregulated CD25 expression. These activation-
induced T-cell changes were reversible since expression of both 
CD6 and CD25 recovered upon stimulus removal. Interestingly, 
CD6 downregulation was observed in CD25+ T  cells indepen-
dently of FoxP3 co-expression. Consequently, CD6 was found 
downregulated on T  cells with both activated and regulatory 
phenotypes, thus arguing against being a characteristic exclusive 
of human Treg as recently proposed (22). Thus, CD6 downregula-
tion would depend on T-cell activation signals irrespective of 
the differentiation pathway (effector or regulatory) that the cell 
undergoes.
The in  vivo occurrence of a small proportion of circulating 
T cells from healthy individuals with downregulated CD6 surface 
expression and diminished alloreactivity was reported some time 
ago (21), although their origin could not be determined. The 
ex vivo analysis presented here demonstrates the expression of 
lower CD6 surface levels on CD25+ T cells from healthy donors 
compared to their CD25− counterparts. In addition, TEM and 
TEMRA subsets from both the CD4+ and CD8+ compartments 
expressed significantly reduced CD6 surface levels compared 
to naïve and TCM-cell populations. These data indicate that CD6 
downregulation also occurs in vivo in the context of activation-
related phenomena such as generation of effector memory cells 
(TEM and TEMRA) and are in agreement with a signal strength/
duration-dependent and progressive model by which a naïve 
T-cell progresses to TCM and then to TEM/TEMRA (31, 41).
Different mechanisms by which CD6 functional capabilities 
would be severely afflicted upon lymphocyte activation-related 
events have already been reported. Mitogen-activated PBL is 
known to express no less than five different alternatively spliced 
CD6 cytoplamic isoforms involving loss of structural motifs 
relevant to signal-transducing function (42, 43). Likewise, the 
extracellular isoform (CD6Δ3) lacking the CD166/ALCAM-
binding domain (D3) of CD6—and consequently unable to 
localize at the APC–T-cell interface during IS formation—is 
upre gulated and dominates upon T-cell activation (33). The pre-
sent report shows shedding of membrane-bound CD6 as an addi-
tional mechanism previously suspected but unproven (24, 25). 
However, we cannot exclude other alternative and/or comple-
mentary mechanism contributing to CD6 down-modulation, 
as it is the case of internalization via coated pits or c-Cbl-
mediated ubiquitination previously reported for CD5 (44–46). 
The surface receptor levels are often regulated by endocytosis 
and subsequent lysosomal degradation or recycling to plasma 
membrane, depending on whether they are ubiquitinated or 
not. The Cbl family of ubiquitin ligases is highly expressed 
in T cells and deeply involved in negative regulation of T-cell 
activation. Available evidence points to the role of Cbl ligases 
in regulating the surface levels of CD5 (44, 47), and this could 
also apply to the sister molecule CD6. Thus, T-cell activation 
could contribute to reduced CD6 surface levels by both pro-
teolytic events and Cbl-mediated ubiquitination, which could 
be direct or indirect through its physical association with CD5. 
Regarding the putative contribution of alternative splicing to 
membrane-bound CD6 down-modulation, available reports by 
independent groups (33, 42, 43) have not identified alternatively 
spliced mRNAs coding for sCD6 and/or CD6 isoforms devoid of 
its entire extracellular region.
The present data indicate that CD6 shedding is due to proteo-
lytic cleavage by, at least in part, members of the ADAM family of 
metalloproteinases. TACE/ADAM17 is known to generate solu-
ble forms of several lymphocyte surface receptors (e.g., CD62L, 
CD16, CD166/ALCAM, ICOS ligand, and FasL) in the context 
FigUre 7 | CD6 surface levels correlate T-cell viability and proliferative capability. PBLs (5 × 107) exposed to PHA (2 µg/mL) for 3 days were subjected to cell sorting 
for isolation of CD3+CD25+ CD6lo/− and CD6hi subsets. Sorted cells were plated (105/well) either with media alone (a,B) or stained with CFSE and co-cultured with 
allogeneic staphylococcal enterotoxin B (SEB)-loaded mature DC (mDC) (2 × 103) (c–e) for 6 days. (a) Number of total live cells (measured by trypan blue dye 
exclusion) at different time points are represented. (B) Left, representative dot plots of Annexin-V-FITC and 7-AAD staining of CD25+CD6lo/− and CD25+CD6hi cells at 
day 6 post-sorting. Right, bar chart representing the percent of live cells (Annexin-V− 7-AAD−), end apoptotic (Annexin-V+ 7-AAD+) and early apoptotic (Annexin-V+ 
7-AAD−) cells. (c) Representative histogram showing CFSE staining of sorted CD25+CD6hi and CD25+CD6lo/− T cells co-cultured with SEB-loaded mDC for 6 days. 
(D) Percentage of proliferating (CFSElo/−) CD25+CD6hi and CD25+CD6lo/− cells at days 2 and 6 post co-culture with allogeneic SEB-pulsed mDC is shown. Data are 
mean ± SD of triplicates from a representative experiment of two performed. *p < 0.05; **p < 0.01; ***p < 0.001 (unpaired t test).
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FigUre 8 | CD6 surface expression attenuates T-cell receptor-independent induced apoptosis in leukemic cells. (a) CD6 expression in parental (CD6−) and stably 
CD6-transfected (CD6+) 2G5 Jurkat T cells. (B) Representative dot plots showing CD6 and CD3 expressions in parental (top) and CD6-transfected (bottom) 2G5 
cells before (day 0) and after (day 1 and 2) PHA (2 µg/mL) stimulation. (c) Percent of live cells (Annexin-V− 7-AAD−) in CD6− and CD6+ 2G5 cells exposed to 
increasing concentrations of doxorubicin or puromycin for 1 day. Results represent mean ± SD of triplicates from one representative experiment of two performed. 
*p < 0.05; **p < 0.01; ***p < 0.001 (unpaired ANOVA test followed by Bonferroni posttest).
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of cell activation (36, 48–51) and would be a feasible candidate. 
However, the fact that CD6 down-modulation was induced by 
ionomycin but not by PMA (Figure 4A) would favor the putative 
involvement of ADAM10, as reported for other transmembrane 
receptors (52).
The functional role of sCD6 release in T-cell physiology is 
uncertain. Available in vitro evidence shows that sCD6 interferes 
with T-cell activation and IS maturation (1, 9, 10). Based on this, 
it can be speculated that sCD6 would act as a “decoy receptor” 
contributing to the inactivation of bystander T cells at inflamma-
tion sites. In any case, the data collectively point to the existence 
of different levels of the regulation of human CD6 function dur-
ing late T-cell activation, all of them involving physical loss of 
relevant extracellular and/or intracytoplasmic regions.
Interestingly, CD6 downregulation was not observed upon 
in vitro activation of mouse T cells or ex vivo analysis of spleen 
CD25+ (either FoxP3+ or FoxP3−) T  cells (Figures S4A,B in 
Supplementary Material), thus stressing the existence of inter-
species differences. Nevertheless, the modulation of mouse CD6 
function by mechanisms other than surface downregulation 
(e.g., expression of alternatively spliced extracellular and/or 
intracytoplasmic isoforms) is still possible and would deserve 
further investigation.
The functional consequences of human CD6 downregulation 
reported here are (i) impaired T-cell proliferative capabilities and 
(ii) higher susceptibility to apoptosis (namely AICD), as deduced 
from the analysis of in vitro-generated and sorted CD25+CD6lo/− 
and CD25+CD6hi cells. The former is illustrated by the lower 
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numbers of cycling CD25+CD6lo/− lymphocytes observed upon 
stimulation with SEB-loaded allogeneic mDC, as compared to 
their CD25+CD6hi counterparts. This agrees with the critical role 
assigned to CD6–CD166/ALCAM interaction for IS formation 
and maturation (9–11) as well as for TCR signaling (17). The 
higher levels of apoptotic cells and of AICD markers (CD95/Fas 
and CD178/FasL) in CD25+CD6low/− T cells also agree with the 
anti-apoptotic properties assigned to CD6 (39). Ligation of CD6 
on T cells by specific mAbs or CD166/ALCAM activates the MAPK 
cascade (14), which is known to result in higher levels of mcl-1 
and promotion of cell survival (53). A similar mechanism would 
apply for the modulation of bcl-2/Bax equilibrium observed in 
B cells following IgM-induced apoptosis (39). The positive effect 
of CD6 in T-cell survival and proliferation would not be restricted 
to humans as CD6-deficient mouse T cells also exhibit a limited 
proliferation and increased apoptosis following in vitro activation 
(54). The intriguing fact is that the anti-apoptotic effect of CD6 
is not necessarily linked to TCR cross-linking, since it is also 
evidenced upon corticosteroid (39), Galectin-1 and -3 (27), and 
as shown here, genotoxic-induced apoptosis, which all by-pass 
such a relevant lymphocyte receptor complex. Indeed, the sole 
presence of CD6 was sufficient to reduce the deleterious effects 
of doxorubicin or puromycin in leukemic Jurkat T cells. These 
results not only confirm the TCR-independent anti-apoptotic 
properties of CD6 but also open the possibility of sensitizing CD6-
positive leukemic T cells to increase the efficacy and/or reduce 
the toxicity of chemotherapeutic agents as recently proposed (55).
Altogether, the present report provides new insight into the 
origin of sCD6 and the circulating CD6− T-cell subset reported 
long ago (21, 24), as well as into the functional consequences of 
CD6 down-modulation on ongoing T-lymphocyte responses. 
The observed effects on the attenuation of T-cell proliferative 
responses and sensitization to apoptotic events place CD6 as a 
new player in T-cell homeostatic processes.
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